论文部分内容阅读
目的评价超早期脑梗死尿激酶溶栓治疗的临床疗效及安全性。方法选择发病6h内的超早期脑梗死患者58例,应用国产尿激酶100～150万单位+生理盐水100ml持续30min静脉滴注,之后给予脱水减轻脑水肿、改善脑循环、保护脑细胞治疗,溶栓治疗24h后头颅CT如无出血常规给予抗血小板治疗,观察溶栓治疗前后神经功能缺损评分变化。结果 58例患者中基本痊愈18例,显著进步21例,进步15例,无变化3例,恶化1例。结论在严格掌握溶栓适应证基础上应用尿激酶静脉溶栓治疗超早期脑梗死安全有效。
Objective To evaluate the clinical efficacy and safety of urokinase thrombolysis in patients with early-stage cerebral infarction. Methods Fifty-eight patients with ultra-early cerebral infarction within 6 hours after onset of symptoms were treated with 100-150,000 units of urokinase plus 100ml of normal saline for 30 minutes. Afterwards, dehydration was given to relieve cerebral edema, improve cerebral circulation and protect brain cells. Hypothyroidism 24h after the head CT if no bleeding given antiplatelet therapy, observe the changes of neurological deficit score before and after thrombolytic therapy. Results In 58 patients, 18 cases were basically cured, 21 cases improved significantly, 15 cases improved, 3 cases did not change and 1 case aggravate. Conclusion It is safe and effective to apply intravenous thrombolytic therapy of urokinase on the basis of strict indications of thrombolytic therapy in patients with ultra-early cerebral infarction.